Hematologic Oncology | Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis from the 2020 ASH Annual Meeting

published 1 month ago by Dr Neil Love

Featuring an interview with Dr Natalie S Callander, including the following topics: Treatment of high-risk smoldering multiple myeloma (MM) with carfilzomib, lenalidomide and dexamethasone followed by maintenance lenalidomide: A Phase II clinical and correlative study (0:00) Early versus late autologous stem cell transplant for newly diagnosed MM: Long-term follow-up analysis of the IFM 2009 trial (3:27) Updated analysis of the GRIFFIN trial: Daratumumab with lenalidomide, bortezomib and dexamethasone for patients with transplant-eligible newly diagnosed MM (14:48) Results from the ANDROMEDA trial evaluating bortezomib, cyclophosphamide and dexamethasone with or without daratumumab for newly diagnosed amyloid light chain (AL) amyloidosis (17:20) Interim analysis of the IKEMA trial evaluating depth of response and response kinetics with isatuximab added to carfilzomib and dexamethasone for relapsed/refractory (R/R) MM (21:23) KarMMa trial: Efficacy and safety of idecabtagene vicleucel in elderly patients with R/R MM (27:55) CARTITUDE-1: Phase Ib/II study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed CAR (chimeric antigen receptor) T-cell therapy, for R/R MM (37:21) Activity and safety of the bispecific antibodies talquetamab and cevostamab (BFCR4350A) in patients with R/R MM (42:21) ANCHOR trial: Updated efficacy and safety of melflufen with either dexamethasone/daratumumab or dexamethasone/bortezomib for R/R MM (47:25) Iberdomide in combination with dexamethasone, daratumumab or both and with dexamethasone/bortezomib for patients with R/R MM (52:39) ALGONQUIN trial: Efficacy and tolerability of belantamab mafodotin with pomalidomide/dexamethasone for patients with R/R MM (55:33) Selinexor in combination with pomalidomide and dexamethasone for R/R MM (57:29) Phase II SWOG-S1702 study of isatuximab for patients with previously treated AL amyloidosis (1:00:17) Safety and efficacy of CAEL-101 in patients with AL amyloidosis on a Phase II dose selection study (1:02:02) Five-year follow-up of ibrutinib with rituximab for Waldenström macroglobulinemia (WM): Final analysis from the Phase III iNNOVATETM study (1:04:06) Bortezomib in combination with dexamethasone, rituximab and cyclophosphamide as first-line treatment for WM: Results of a randomized Phase II trial (1:07:11) Roles of zanubrutinib and acalabrutinib for WM (1:09:40) CME information and select publications

more episodes from Research To Practice | Oncology Videos